Feasibility of the utilization of BNCT in the fast neutron therapy beam at Fermilab
The Neutron Therapy Facility at Fermilab has treated cancer patients since 1976. Since then more than 2,300 patients have been treated and a wealth of clinical information accumulated. The therapeutic neutron beam at Fermilab is produced by bombarding a beryllium target with 66 MeV protons. The resulting continuous neutron spectrum ranges from thermal to 66 MeV in neutron energy. It is clear that this spectrum is not well suited for the treatment of tumors with boron neutron capture therapy (BNCT) only However, since this spectrum contains thermal and epithermal components the authors are investigating whether BNCT can be used in this beam to boost the tumor dose. There are clinical scenarios in which a selective tumor dose boost of 10 - 15% could be clinically significant. For these cases the principal treatment would still be fast neutron therapy but a tumor boost could be used either to deliver a higher dose to the tumor tissue or to reduce the dose to the normal healthy tissue while maintaining the absorbed dose level in the tumor tissue.
- Research Organization:
- Fermi National Accelerator Lab. (FNAL), Batavia, IL (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research (ER) (US)
- DOE Contract Number:
- AC02-76CH03000
- OSTI ID:
- 756969
- Report Number(s):
- FERMILAB-TM-2118; TRN: US0003734
- Resource Relation:
- Other Information: PBD: 23 Jun 2000
- Country of Publication:
- United States
- Language:
- English
Similar Records
Clinical trial of BNCT for glioblastoma multiforme
Clinical phase-I study of Na[sub 2]B[sub 12]H[sub 11]SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT)